机构：[1]Department of Oncology The First Hospital Affiliated To Army Medical University (Southwest Hospital) Chongqing, China[2]Genecast Precision Medicine Technology Institute Beijing, China[3]Pathology Department The First Hospital Affiliated To Army Medical University (Southwest Hospital) Chongqing, China[4]Department of Second Internal Medicine The People's Hospital of Huaying Sichuan Province Huaying, China[5]Institute of Infectious Diseases Beijing Ditan Hospital Capital Medical University Beijing, China
第一作者机构：[1]Department of Oncology The First Hospital Affiliated To Army Medical University (Southwest Hospital) Chongqing, China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Oncology The First Hospital Affiliated To Army Medical University (Southwest Hospital) Chongqing, China[*1]Department of Oncology, The First Hospital Affiliated To Army Medical University (Southwest Hospital), Yanzheng Street 30, Shapingba dis., Chongqing 400038, China
推荐引用方式(GB/T 7714)：
Yu Peng,Lei Zhang,Tian Zeng,et al.Characterization of Hyperprogression After Immunotherapy in a Lung Adenocarcinoma Patient With Strong Expression of Programmed Death Ligand 1[J].JOURNAL OF THORACIC ONCOLOGY.2020,15(1):E4-E8.doi:10.1016/j.jtho.2019.08.007.
APA：
Yu Peng,Lei Zhang,Tian Zeng,Li Liu,Xingli Liu...&Zhihua Ruan.(2020).Characterization of Hyperprogression After Immunotherapy in a Lung Adenocarcinoma Patient With Strong Expression of Programmed Death Ligand 1.JOURNAL OF THORACIC ONCOLOGY,15,(1)
MLA：
Yu Peng,et al."Characterization of Hyperprogression After Immunotherapy in a Lung Adenocarcinoma Patient With Strong Expression of Programmed Death Ligand 1".JOURNAL OF THORACIC ONCOLOGY 15..1(2020):E4-E8
医学